Characterization of the cell-mediated immune response to Takeda’s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting-Reference-Cited by-同舟云学术

Characterization of the cell-mediated immune response to Takeda’s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting

Published:2022-02 Issue:8 Volume:40 Page:1143-1151
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Tricou Vianney,Gottardo Raphael,Egan Michael A.,Clement Frédéric,Leroux-Roels Geert,Sáez-Llorens Xavier,Borkowski Astrid,Wallace Derek,Dean Hansi J.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference42 articles.

1. World Health Organization. Dengue and severe dengue. Available at: http://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue [accessed 22 September 2021].

2. Dengue: an update;Guzmán;Lancet Infect Dis,2002

3. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection;Guzman;Arch Virol,2013

4. Antibody-dependent enhancement of severe dengue disease in humans;Katzelnick;Science,2017

5. Common occurrence of concurrent infections by multiple dengue virus serotypes;Beaty;Am J Trop Med Hyg,1999

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, public health impact and optimal use of the Takeda dengue vaccine;2024-08-11

2. Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis;Vaccines;2024-07-13

3. CD4+ T Cell Depletion Before Primary Dengue and/or Secondary Zika Infection Reveals Mechanistic Correlates of Antibody Functionality in Rhesus Macaques;2024-02-22

4. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial;The Lancet Global Health;2024-02

5. Dengue Vaccination: Towards a New Dawn of Curbing Dengue Infection;Immunological Investigations;2023-11-14